Anmeldung erfolgt in Kürze...
Details werden geladen...
Novartis Pharma AG: FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in combination
Ähnliche Seiten
Press Release: Novartis: FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care acros... | 31.07.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/press-release-novartis-fda-approves-pluvicto-for-psma+-metastatic-hormone-sensitive-prostate-cancer-mhspc-advancing-potential-new-standard-of-care-acros--1036394720
FDA Approves Novartis' Pluvicto Combo For Metastatic Hormone-sensitive Prostate Cancer
https://www.finanznachrichten.de/nachrichten-2026-08/69190580-fda-approves-novartis-pluvicto-combo-for-metastatic-hormone-sensitive-prostate-cancer-020.htmFDA Approves Novartis' Pluvicto Combo For Metastatic Hormone-sensitive Prostate Cancer | 01.08.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/fda-approves-novartis-pluvicto-combo-for-metastatic-hormone-sensitive-prostate-cancer-1036395535
FDA Approves Novartis' Pluvicto Combo For Metastatic Hormone-sensitive Prostate Cancer | 01.08.26 | finanzen.at
https://www.finanzen.at/nachrichten/aktien/fda-approves-novartis-pluvicto-combo-for-metastatic-hormone-sensitive-prostate-cancer-1036395535Novartis Pharma AG: Pluvicto demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
https://www.finanznachrichten.de/nachrichten-2026-05/68637358-novartis-pharma-ag-pluvicto-demonstrated-consistent-efficacy-across-key-patient-subgroups-in-metastatic-hormone-sensitive-prostate-cancer-399.htm